Investing in Cancer Stocks

Learn about some of the leading cancer stocks in the U.S. stock market this year.

By Keith Speights – Updated Oct 31, 2025 at 9:37 PM | Fact-checked by Frank Bass

Key Points

Investing in cancer stocks offers potential returns from an unfortunately large market.
Sector spending could hit $245 billion by 2030, according to one estimate.
Liquid biopsy tests by Guardant Health are gaining FDA approval, broadening early cancer detection.

Loading paragraph...

Two scientists looking at a monitor showing brain scans. — Image source: Getty Images.

Loading paragraph...

Ticker Information Table
Name and ticker	Market cap	Dividend yield	Industry
Guardant Health (NASDAQ:GH)	$12.1 billion	0.00%	Healthcare Providers and Services
Illumina (NASDAQ:ILMN)	$18.5 billion	0.00%	Life Sciences Tools and Services
Pfizer (NYSE:PFE)	$141.3 billion	6.88%	Pharmaceuticals
Summit Therapeutics (NASDAQ:SMMT)	$13.7 billion	0.00%	Biotechnology

Data as of Nov 7, 2025.

Loading ticker_table...

Loading paragraph...

NASDAQ: GH

Guardant Health

Today's Change

(1.26%) $1.20

Current Price

$96.25

Key Data Points

Market Cap

$12B

Day's Range

$89.68 - $97.51

52wk Range

$28.20 - $100.22

Volume

Avg Vol

2.8M

Gross Margin

63.76%

Dividend Yield

N/A

Loading paragraph...

NASDAQ: ILMN

Illumina

Today's Change

(-1.10%) $-1.35

Current Price

$121.09

Key Data Points

Market Cap

$19B

Day's Range

$118.55 - $124.04

52wk Range

$68.70 - $155.99

Volume

102K

Avg Vol

1.7M

Gross Margin

66.79%

Dividend Yield

N/A

Loading company_card...

Loading paragraph...

NYSE: PFE

Pfizer

Today's Change

(1.28%) $0.32

Current Price

$24.93

Key Data Points

Market Cap

$141B

Day's Range

$24.55 - $25.12

52wk Range

$20.91 - $27.69

Volume

2.7M

Avg Vol

57M

Gross Margin

69.12%

Dividend Yield

0.07%

Loading company_card...

Loading paragraph...

NASDAQ: SMMT

Summit Therapeutics

Today's Change

(2.10%) $0.38

Current Price

$18.45

Key Data Points

Market Cap

$14B

Day's Range

$17.90 - $18.99

52wk Range

$15.55 - $36.91

Volume

2.2M

Avg Vol

4.1M

Gross Margin

0.00%

Dividend Yield

N/A

Loading company_card...

Loading paragraph...

Related investing topics

Loading paragraph...

Investing in Marijuana Stocks

The continued legalization of marijuana means growth for companies in this sector.

Best Psychedelic Stocks to Buy in 2025

It turns out that "magic mushrooms" may have medical applications. Here's what you need to know.

Best Stocks to Buy in November 2025

Ten stocks that could be great buys for long-term investors looking to put their money to work.

Investing in the Best Healthcare Stocks

Healthcare is a universal need. Companies in this broad-based sector can produce healthy returns.

Loading paragraph...

Loading faq...

About the Author

Keith Speights is a contributing Motley Fool healthcare analyst covering publicly traded companies across pharmaceuticals, biotechnology, medical devices, technology, and marijuana. Prior to The Motley Fool, Keith was CEO of Constant Care Technology, a healthcare technology company; vice president of American HealthTech, a healthcare software company; and a director of operations for Blue Cross Blue Shield of Mississippi, a health insurer. He holds a B.S. in Industrial Engineering from Mississippi State University.

TMFFishBiz

Keith Speights has positions in Bristol Myers Squibb and Pfizer. The Motley Fool has positions in and recommends Amgen, Bristol Myers Squibb, Guardant Health, Merck, Pfizer, and Summit Therapeutics. The Motley Fool recommends AstraZeneca Plc, Grail, Illumina, and Johnson & Johnson. The Motley Fool has a disclosure policy.